Polyclonal Resistance in Gastrointestinal Stromal Tumor Treated with Sequential Kinase Inhibitors

To the Editor: We read with interest the article by Wardelmann et al. ([1][1]) describing the evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors (GIST) associated with resistance to treatment with imatinib mesylate. We have witnessed a similar emergence of multiple

[1]  J. Desai,et al.  Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Blay,et al.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.

[3]  F. Romanelli,et al.  Advances in Human Immunodeficiency Virus Therapeutics , 2006, The Annals of pharmacotherapy.

[4]  E. Wardelmann,et al.  Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate , 2006, Clinical Cancer Research.

[5]  M. van Glabbeke,et al.  Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[7]  P. Marynen,et al.  Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.

[8]  B. Druker.  Overcoming resistance to imatinib by combining targeted agents. , 2003, Molecular cancer therapeutics.

[9]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.